CDK5 and neoplasm: The combination of increased CDK5 levels and oxaliplatin treatment repressed tumor growth by 79.0% compared to increased CDK5 levels alone, whereas oxaliplatin treatment alone moderately inhibited tumor growth in control cells (tumor inhibition rate = 50.2%) (Fig. 4F H).